In a first for adults in Singapore, scientists are conducting gene editing trials on heart patients to correct defects at ...

Some of the most expensive drugs currently in use are gene therapies to treat specific diseases, and their high cost limits ...

The company intends to divest Roctavian and “remove it from our portfolio,” CEO Alexander Hardy said, after nearly three ...

Despite challenges like high costs and regulatory complexities, Europe's vibrant research ecosystem and EMA's supportive ATMP ...

4D Molecular Therapeutics has sold the Asia-Pacific rights to its eye gene therapy to Otsuka Pharmaceutical, securing $85 ...

Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing ...

Oncologists' experience with CGT has increased, with more patients treated and earlier lines of therapy being utilized.

Long-term follow-up shows 95% success rate, no serious complications in largest ADA-SCID gene therapy study to date ...

A top US regulator plans to unveil a faster approach to approving custom gene-editing treatments, a move designed to unleash a wave of industry investment that will yield cures for patients with rare ...

The trial was small — just 12 children were treated in one or both ears — but it offers important lessons for researchers about the potential of Regeneron’s gene therapy.

Hyderabad- and Cambridge-based biotech startup Helex will use the capital to advance its gene therapy platform and develop ...

The startup is developing genomic medicines for kidney diseases using advanced lipid nanoparticle (LNP) technology to deliver ...